Visiongain Publishes CBD Nutraceuticals Market Report 2020-2030

30 June 2020
Pharma

Visiongain has launched a new pharma report CBD Nutraceuticals Market Report 2020-2030: Forecasts by Product Type (CBD Tinctures, CBD Gummies, Capsules & Softgels, Others), Sales Channel (Retail Stores, Online, Pharmacies), and Geography (North America, Latin America, Europe, Asia Pacific, MEA).

The global CBD Nutraceuticals Market is anticipated to grow at a lucrative CAGR of ~xxx% and anticipated to reach USD xxx billion by 2020. Visiongain anticipates that the market will witness lucrative growth rates owing to growing consumer preferences for plant-based supplements and growing awareness regarding numerous health benefits associated with the CBD nutraceuticals.

With the passing of the Farm Bill in 2018, cannabinoids (CBD) are valued to grow more than $xxx billion by 2025, with much of the demand in foods, beverages, dietary supplements, and topical skin care products. Currently, the Food and Drug Administration prohibits CBD in food and dietary supplements because such compounds are active ingredients in approved drugs. Until this law changes, the large growth projected for CBD may shift, focusing on topical products only.

To access the data contained in this document please email contactus@visiongain.com

The global CBD nutraceutical market was dominated by CBD tinctures in 2019. One of the key drivers of demand is the increased use of CBD tinctures, thanks to their high bioavailability as compared to oils to alleviate severe pain, anxiety, and stress. These tinctures will continue to fuel the segment growth through the forecast period, in different volumes and concentrations, according to individual demands.

However, capsules & softgels segments are anticipated to witness the highest growth over the forecast period, because these products are more comfortable and easier to use. Many users switch to soft gels and capsules because they dislike tinctures' taste and texture, making it difficult to consume every day.

Due to increasing demands for functional (FF), Functional Drinks (FB), and Dietary Supplements (DS), North America dominated the world market in nutraceutical CBD in the United States because of increased consciousness of their benefits for health and an increase in disposable income.

Due to the increased legalization and promising guidance in respect for use of cannabidiol in the regional countries, the Asia-Pacific region is expected to grow the highest CAGR over the forecast period. Thailand removed hemp and petroleum from the controlled substances list in September 2019 and is expected to extend the use of CBD in the country to include health supplements. Several CBD nutraceutical companies are planning to become involved in the Asian market, which is anticipated to fuel regional growth. Growth will also be driven by increased awareness about the use of CBD nutraceuticals to health and well-being purposes.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations, and launching new products to strengthen their position in the global CBD nutraceuticals market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the CBD Nutraceuticals Market.

For instance, on 17th April 2019; MGC Pharmaceuticals Ltd. signed a marketing, sales, and distribution agreement to provide its CBD and hemp-enhanced Nutraceutical product line into the Chinese health products market through a tailored campaign designed with Chinese specialist e-commerce retailer YuShop Global (“YuShop”).

The comprehensive market report features companies such as Charlotte’s Web, CV Sciences, Inc., Diamond CBD, Elixinol, Irwin Naturals, Isodiol, Endoca, Medical Marijuana Inc., MGC Pharma among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Clinical Trials Market Report 2020-2030

With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.

01 July 2020

Read

Visiongain Publishes Clinical Risk Grouping Solutions Market Report 2020-2030

The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.

01 July 2020

Read

Visiongain Publishes Clinical Perinatal Software Market Report 2020-2030

Various research studies are currently underway, which are expected to create a competitive advantage for manufacturers to develop new and innovative and advanced software that is expected to provide a variety of additional opportunities in the perinatal clinical software market.

01 July 2020

Read

Visiongain publishes Clinical Laboratory Tests Market Report 2020-2030

Growing investment in target diagnosis of cardiovascular disorders, TB and diabetes drives demand for clinical laboratory testing. Clinical lab tests help in diagnosing mellitus diabetes. According to the International Diabetes Federation article published in 2019, some 463 million adults were diabetic, and it is estimated that it will reach 700 million worldwide by 2045.

01 July 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever